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Stage-specific incidence trends of melanoma in an English
region, 1996–2015: longitudinal analyses of
population-based data
Annie Herberta, Minjoung M. Kooa, Matthew E. Barclayb,c, David C. Greenbergb,
Gary A. Abeld, Nick J. Levelle and Georgios Lyratzopoulosa,b,c
The aim of this study was to examine temporal trends in
overall and stage-specific incidence of melanoma. Using
population-based data on patients diagnosed with
melanoma in East Anglia, England, 1996–2015, we
estimated age-standardized time trends in annual incidence
rates for each stage at diagnosis. Negative binomial
regression was used to model trends over time adjusted for
sex, age group and deprivation, and to subsequently
examine variation in stage-specific trends by sex and age
group. The age-standardized incidence increased from 14 to
29 cases/100 000 persons (i.e. 4% annually). Increasing
incidence was apparent across all stages but was steepest
for stage I [adjusted annual increase: 5%, 95% confidence
interval (CI): 5–6%, and more gradual for stage II–IV disease
(stage II: 3%, 95% CI: 2–4%; stage III/IV: 2%, 95% CI:
1–3%)]. Stage II–IV increase was apparent in men across
age groups and in women aged 50 years or older. Increases
in incidence were steeper in those aged 70 years or older,
and in men. The findings suggest that both a genuine
increase in the incidence of consequential illness and a
degree of overdiagnosis may be responsible for the
observed increasing incidence trends in melanoma in our
population during the study period. They also suggest the
potentially lower effectiveness of public health awareness
campaigns in men and older people. Melanoma Res
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Introduction
The incidence of melanoma has increased dramatically in
countries with predominantly White populations in
recent decades and is projected to continue to increase
for several countries [1–4].
Two key potential drivers of increasing incidence are
increased population exposure to ultraviolet radiation
(the principal known environmental risk factor for
melanoma) [5], and overdiagnosis of tumours that would
not spread during that patient’s lifetime [6,7]. The former
hypothesis (actual increase in the incidence of con-
sequential illness) concords with increasing recreational
exposure to sunlight since the 1950s [8,9]. However,
stable trends in melanoma mortality despite increasing
incidence have been observed, which may reflect either
earlier diagnosis and more effective treatment of
increasing consequential illness, or increasing over-
diagnosis of relatively indolent lesions [10–14].
Analyses of stage-specific time trends of melanoma
incidence could help to provide insights into mechanisms
underlying increasing incidence: genuine increases in
ultraviolet radiation exposure could be assumed to result
in increased incidence of each stage equally, while
overdiagnosis may lead to a disproportionately greater
increase in early stage disease. Levell et al. [13] reported
increasing incidence trends for stage I–III melanoma in
1991–2004, with a steeper increase for stage I disease.
However, it is important to examine more recent patient
cohorts, and potential differences in stage-specific varia-
tion over time by the sociodemographic group [15].
Patients and methods
Data
We analysed anonymized data on cases of primary inva-
sive malignant melanoma (International Classification of
Diseases for Oncology-3 code C43) diagnosed during
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1996–2015 in East Anglia, UK, for patients aged 15 years
and older. These data were collected initially by the
population-based cancer registry for the Anglia subregion
of the East of England, and successor organizations who
took over responsibility (currently the Public Health
England National Cancer Registration and Analysis
Service).
Patients who were first diagnosed with melanoma in
the 15 years before the study period (1981–1995)
(n= 309/10 199) were a priori excluded from analyses,
while for those with multiple tumours diagnosed during
the study period (1996–2015), the earliest diagnosis was
selected [16,17]. For patients with more than one tumour
in a given year, the tumour with the more advanced stage
at diagnosis was included.
Information was available on the year of diagnosis, stage
at diagnosis, sex, age group (15–49 years and 5-year age
groups thereafter), deprivation group, the method of
diagnosis (e.g. histological or other basis) and survival
status to death or censoring. Tumour stage was assigned
by registry staff on the basis of clinical, imaging, and
pathological information according to the 4th edition of
the TNM classification (i.e. unified AJCC/UICC classi-
fications) [18]. We combined stage III and IV cases into a
single ‘advanced stage’ category, because of the small
number of stage IV cases (n= 155/9890). The deprivation
measure used was the Index of Multiple Deprivation
(IMD) quintiles (fifths) of the income domain scores for
the Lower Super Output Area of the patient’s residence
at diagnosis: IMD 2004 for diagnoses in 1996–2002; IMD
2007 for 2003–2006; IMD 2010 for 2007–2011; IMD
2015 for 2012–2015. As we used all available data for the
period 1996–2015, a sample size calculation was not carried
out.
Statistical analysis
Our general approach was to calculate incidence rates by
treating the number of melanoma cases as the numerator
and the estimated mid-year population residing within
the boundaries of East Anglia as the denominator.
Population estimates were stratified by the year of diag-
nosis, sex, age group and deprivation [19]. All analyses
were performed in Stata v.13 (StataCorp., College
Station, Texas, USA).
We first summarized the numbers of melanoma cases by
sex, age group, deprivation, and stage, overall and by
5-year diagnosis periods. As 5.0% of patients (493/9890)
had no recorded stage at diagnosis, we used multiple
imputation before the main analyses – see below [20,21].
In a sensitivity analysis, we carried out a ‘complete case
analysis’ (i.e. on those with nonmissing stage, n= 9397).
Incidence trends, by stage
We presented overall incidence trends and stage-specific
incidence trends, by plotting sex-specific age-standardized
rates (using the European Standard Population 2013) by
year [22], for all cases and by stage at diagnosis. We plotted
these trends on the log-scale, to allow a fair representation
of relative changes over time among stage groups with
different baseline incidence rates.
We initially considered the Poisson model for assessing
temporal trends while adjusting for stage, sex, age group,
deprivation and the interaction term stage× year, but
variability in incidence rates was larger than assumed by
the Poisson model (P< 0.0001). Hence, we adopted
negative binomial models that include an additional
parameter for variance overdispersion (‘Model 1’ in Box
S1, Supplemental digital content 1, http://links.lww.com/
MR/A60) [23].
Negative binomial models provided estimates of adjus-
ted incidence rate ratios (IRRs). The IRR for the inde-
pendent variable year (hereafter referred to as the ‘annual
IRR’) represents the percentage increase in incidence
per year as: (IRR− 1)× 100 (e.g. an annual IRR of 1.05 is
equivalent to a 5% increase per year).
Stage-specific incidence trends, by patient group
We explored whether stage-specific incidence trends
varied by patient group, by investigating whether
including three-way and four-way interaction terms
between the two demographic variables (age and sex)
and the stage× year interaction improved the fit of the
original negative binomial model (which included main
effects variables for stage, sex, age group, deprivation,
year and the interaction stage× year). The investigation
of interaction terms was performed using a step-wise
process. We included interactions with demographic
variables in descending order of the strength of associa-
tion for the main effects in the original model and used
the likelihood ratio test at each step to assess the
improvement of fit by including the variable at that step.
The final model included the same main effect variables
(i.e. stage, sex, age group, deprivation and year), as well as a
four-way interaction term sex× age group× stage×year (and
its two-way and three-way components; ‘Model 2’ in Box
S1, Supplemental digital content 1, http://links.lww.com/
MR/A60). As this updated model required a substantially
greater number of degrees of freedom, these variables
were more broadly categorized as two stage groups
(I, II–IV); three age groups (15–49, 50–69 and ≥ 70 years);
and three deprivation groups (least deprived, 2nd to
4th quintiles, most deprived). Finally, we calculated the
adjusted annual IRRs for each patient group (all combi-
nations of stage, sex and age group), predicted from this
updated model.
Multiple imputation
We created five datasets (following the generic rule that
the number of imputations should correspond to the
percentage of missing data) [24], where missing stage was
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imputed. We used multinomial logistic regression, on the
basis of sex, age group, deprivation group, survival status,
and the Nelson–Aalen estimator of the cumulative hazard
[25], censoring survival information at 1 year post-
diagnosis, to minimize bias from deaths unrelated to the
melanoma. We carried out analyses as described above
on each of these five datasets, using Rubin’s rules to
combine resulting estimates [26]. In sensitivity analysis,
we carried out a ‘complete case analysis’ by restricting the
analysis sample to only cases with observed stage, and
compared the two approaches as the percentage change
in the model coefficients (equivalent to the percentage
change in IRRs on the log-scale).
Results
There were 9890 cases of melanoma diagnosed in East Anglia
during 1996–2015 in an approximate population of 2.5 million
during the study period. Table 1 shows the patients’ char-
acteristics by 5-year periods. Just over half (51%) of the cases
were women, and just over half (53%) of the cases were under
65 years of age. Stage I disease accounted for the majority of
cases (62%) during the entire study period. The proportion of
younger patients (15–49 year-olds) decreased over time (from
31% in 1996–2000 to 20% in 2011–2015), while the propor-
tion of stage I cases increased (from 57 to 64%).
Incidence trends, by stage
During the study period, the age-standardized incidence
of melanoma increased substantially from 14.0 per
100 000 in 1996 to 29.4 in 2015 (i.e. by + 4% annually)
(Fig. 1 and Table S1, Supplemental digital content 1,
http://links.lww.com/MR/A60). Overall (all-stage) incidence
rates increased with time with a slight acceleration
around 2005 (women: 15.0 per 100 000 in 1996 to 27.6,
men: 13.3–32.5, Fig. 1). This overall time trend was
mirrored by that for stage I cases, where the age-
standardized incidence increased from 8.2 per 100 000
in 1996 to 20.3 in 2015 (+ 5% annually). Age-standardized
incidence of stage II and stage III/IV cases also increased,
but less steeply than for stage I cases (+ 2.8 and + 1.9%,
annually).
After adjustment for sex, age group and deprivation,
there was strong statistical evidence for increasing inci-
dence in stage I, II, and III/IV disease (P< 0.0001 for all
adjusted annual IRRs), but a steeper increase for stage I
disease [adjusted annual IRR for stage I disease: 1.05,
i.e., a 5% increase per year, 95% confidence interval (CI):
1.05–1.06; stage II: 1.03, i.e., 3% increase per year, 95%
CI: 1.02–1.04; stage III/IV: 1.02, i.e., 2% increase per
year, 95% CI: 1.01–1.03; Table 2].
Stage-specific incidence trends, by sex–age subgroups
There was an increasing incidence of stage I disease for
all age-sex strata, with adjusted annual IRR estimates
significantly greater than 1 for all groups [lower bounds of
95% CIs for IRRs ranged from 1.01 to 1.10 (Fig. 2 and
Table 3)]. Larger increases in the incidence of stage 1
disease over time were seen with increasing age [e.g.
adjusted annual IRR for women, ≥ 70 years: 1.08 (95%
CI: 1.08–1.09), women overall: 1.04 (95% CI: 1.04–1.05)].
Within each age group, adjusted annual IRRs were larger
for men than women.
Table 1 Demographic and clinical characteristics of primary melanoma cases diagnosed in East Anglia during 1996–2015 (split into 5-year
periods)
1996–2000 2001–2005 2006–2010 2011–2015 1996–2015 (Total study period)
Total 1516 (100.0) 2033 (100.0) 2955 (100.0) 3386 (100.0) 9890 (100.0)
Sex
Female 844 (55.7) 1095 (53.9) 1465 (49.6) 1675 (49.5) 5079 (51.4)
Male 672 (44.3) 938 (46.1) 1490 (50.4) 1711 (50.5) 4811 (48.6)
Age group (years)
15–49 467 (30.8) 553 (27.2) 654 (22.1) 662 (19.6) 2336 (23.6)
50–54 172 (11.3) 175 (8.6) 210 (7.1) 253 (7.5) 810 (8.2)
55–59 150 (9.9) 229 (11.3) 278 (9.4) 264 (7.8) 921 (9.3)
60–64 148 (9.8) 198 (9.7) 391 (13.2) 366 (10.8) 1103 (11.2)
65–69 141 (9.3) 201 (9.9) 324 (11.0) 449 (13.3) 1115 (11.3)
70–74 152 (10.0) 209 (10.3) 353 (11.9) 396 (11.7) 1110 (11.2)
75–79 105 (6.9) 211 (10.4) 305 (10.3) 392 (11.6) 1013 (10.2)
80–84 100 (6.6) 142 (7.0) 233 (7.9) 298 (8.8) 773 (7.8)
>85 81 (5.3) 115 (5.7) 207 (7.0) 306 (9.0) 709 (7.2)
Deprivation (IMD quintile)
1 (Least) 404 (26.6) 481 (23.7) 690 (23.4) 828 (24.5) 2403 (24.3)
2 406 (26.8) 608 (29.9) 880 (29.8) 1022 (30.2) 2916 (29.5)
3 383 (25.3) 532 (26.2) 865 (29.3) 921 (27.2) 2701 (27.3)
4 236 (15.6) 294 (14.5) 385 (13.0) 419 (12.4) 1334 (13.5)
5 (Most) 87 (5.7) 118 (5.8) 135 (4.6) 196 (5.8) 536 (5.4)
Stage at diagnosis
I 863 (56.9) 1192 (58.6) 1935 (65.5) 2150 (63.5) 6140 (62.1)
II 349 (23.0) 449 (22.1) 572 (19.4) 652 (19.3) 2022 (20.4)
III–IV 210 (13.9) 287 (14.1) 382 (12.9) 356 (10.5) 1235 (12.5)
Missing 94 (6.2) 105 (5.2) 66 (2.2) 228 (6.7) 493 (5.0)
IMD, Index of Multiple Deprivation.
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Fig. 1
Age-standardized incidence of melanoma (smoothed and observed) by stage at diagnosis, for (a) women and (b) men. Smoothed rates are ‘lowess’
(locally weighted scatterplot smoothed) (i.e. the average of each observed yearly rate and rates in nearby years; in this case, the bandwidth was set at
0.2). For 493 patients (5% of the entire dataset) with missing values on stage, these values were imputed as described under ‘Multiple imputation’.
Table 2 Adjusted incidence rate ratios of melanomaa
Variables IRR 95% CI P valueb
% Change from IRR in
complete-case analysisc
Increase in incidence per
yeard (%)
Increase in incidence across the study
period 1996–2015e (%)
Sex (ref: female)
Male 1.12 1.07–1.18 <0.0001 6.8 – –
Age group (ref: 65–59 years)
15–49 0.22 0.20–0.24 <0.0001 0.0 – –
50–54 0.56 0.50–0.62 <0.0001 −0.4 – –
55–59 0.67 0.60–0.74 <0.0001 0.4 – –
60–64 0.82 0.74–0.91) 0.0001 2.5 – –
65–69 – – – – – –
70–74 1.18 1.07–1.31 0.0013 −2.3 – –
75–79 1.36 1.23–1.51 <0.001 11.1 – –
80–84 1.45 1.30–1.62) <0.001 7.3 – –
85+ 1.55 1.39–1.74) <0.001 42.3 – –
Deprivation (ref: least deprived)
2 0.94 0.88–1.00 0.064 −21.3 – –
3 0.84 0.78–0.90 <0.0001 4.3 – –
4 0.70 0.65–0.76 <0.0001 −0.9 – –
Most deprived 0.53 0.48–0.59 <0.0001 −0.7 – –
Stage at diagnosis (ref: I)
II 0.44 0.39–0.50 <0.0001 1.0 – –
III and IV 0.30 0.26–0.35 <0.0001 −3.6 – –
Years of diagnosis (by stage at diagnosis)f
Stage I 1.05 1.05–1.06 <0.0001 1.2 5 153
Stage II 1.03 1.02–1.04 <0.0001 −8.2 3 75
Stage III/IV 1.02 1.01–1.03 <0.0001 5.4 2 46
AIC, Akaike Information Criterion; CI, confidence interval; IRR, incidence rate ratio; ref, reference category.
Pseudo-R2 of Model 1=17%, AIC=16 094.
aEstimated from negative binomial model including main effect variables for year, stage, sex, age group, deprivation and interaction stage× year. Exact model form provided
as ‘Model 1’ in Box S1 (Supplemental digital content 1, http://links.lww.com/MR/A60). For 493 patients with missing values on stage (5% of entire dataset), these values
were imputed as described under ‘Multiple imputation’.
bNull hypothesis: IRR=1. Presented up to 4 decimal points and up to two significant figures.
cOn the log-scale (i.e. % change in β coefficients). Median change in model coefficients: 2.1%, interquartile range: −0.9 to 8.3%.
dDerived as: (IRR−1)×100.
eDerived as: (IRR19−1) × 100.
fDerived as: IRR=Exp[β5 year + β6k(stagek× year)]; see Model 1 in Box S1 (Supplemental digital content 1, http://links.lww.com/MR/A60).
4 Melanoma Research 2018, Vol 00 No 00
Considering the respective adjusted annual IRRs for stage
II–IV melanoma, increasing temporal trends in incidence
were observed both in older women [e.g. IRR for≥70 years:
1.03 (95% CI: 1.02–1.03)] and, more so, in older men [e.g.
≥70 years: 1.05 (95%CI: 1.04–1.06)] (Fig. 2 and Table 3). In
younger people (age: 15–49 years) the increase in the
incidence of stage II–IV melanoma was minimal, and not
significant for women [adjusted annual IRR for women: 1.00
(95% CI: 0.99–1.01), P=0.38; men: 1.01 (95% CI:
1.00–1.02), P=0.01]. Increases in rates of stage II–IV dis-
ease were greater in older age, but this gradient was not as
steep as that for stage I disease.
Fig. 2
Estimated incidence rate ratios (IRRs) of (a) stage 1 and (b) stages II–IV melanoma for 2015 (vs. 1996), according to sex and age groups. Displayed
incidence rate ratios for stage-specific disease per year estimated from Model 2, to the power 19 (model form provided in Box S1; Supplemental
digital content 1, http://links.lww.com/MR/A60). For 493 patients with missing values on stage, these values were imputed as described under
‘Multiple imputation’.
Table 3 Adjusted incidence rate ratios of melanoma (both annual and across the entire period 1996–2015) for different patient subgroupsa
Stage I Stages II–IV
Age
Adjusted annual IRR
(95% CI) P valueb
Adjusted IRR for entire periodc
(95% CI)
Adjusted annual IRR
(95% CI)c P valued
Adjusted IRR for entire periodc
(95% CI)
Women
15–49 1.02 (1.01–1.02) <0.0001 1.42 (1.30–1.55) 1.00 (0.99–1.01) 0.38 1.08 (0.91–1.29)
50–69 1.04 (1.04–1.05) <0.0001 2.30 (2.11–2.50) 1.02 (1.01–1.03) <0.0001 1.50 (1.32–1.70)
≥70 1.08 (1.08–1.09) <0.0001 4.57 (4.11–5.07) 1.03 (1.02–1.03) <0.0001 1.71 (1.54–1.90)
Overall 1.04 (1.04–1.05) <0.0001 2.19 (2.01–2.39) 1.02 (1.02–1.03) <0.0001 1.50 (1.35–1.66)
Men
15–49 1.03 (1.02–1.03) <0.0001 1.62 (1.45–1.81) 1.01 (1.00–1.02) 0.014 1.24 (1.04–1.48)
50–69 1.06 (1.05–1.07) <0.0001 3.02 (2.76–3.32) 1.02 (1.01–1.02) <0.0001 1.41 (1.27–1.58)
≥70 1.11 (1.10–1.11) <0.0001 6.84 (6.12–7.64) 1.05 (1.04–1.06) <0.0001 2.54 (2.30–2.82)
Overall 1.06 (1.06–1.07) <0.0001 3.21 (2.93–3.53) 1.04 (1.03–1.04) <0.0001 1.94 (1.76–2.15)
CI, confidence interval; IRR, incidence rate ratio.
aSex-age-stage-specific IRRs were estimated from the updated negative binomial model, which included main effects year, stage, sex, age group, deprivation and four-way
interaction sex× age group× stage× year. Exact model form provided as ‘Model 2’ in Box S1, (Supplemental digital content 1, http://links.lww.com/MR/A60). Overall
IRRs were estimated according to Model 1 (form provided in Box S1, Supplemental digital content 1, http://links.lww.com/MR/A60). For 493 patients with missing values
on stage (5% of the entire sample), these values were imputed as described under ‘Multiple imputation’.
bNull hypothesis: IRR=1. Presented up to 4 decimal points and up to two significant figures.
cCalculated as adjusted annual IRR to the power 19.
dNote that in 15–49-year-old men, the 95% CI of the adjusted annual IRR for stages II–IV contains 1.00 but the P value is 0.014, because of rounding to two decimal
places.
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The complete-case sensitivity analyses produced similar
results to those obtained in the main analyses, where
missing stage was imputed (also see Table 2 and Fig. S1
and Table S2, Supplemental digital content 1, http://links.
lww.com/MR/A60).
Discussion
Summary of main findings
The age-standardized incidence of melanoma increased
substantially in the East Anglia region during 1996–2015.
This increase predominantly reflected the increasing
incidence of stage I cases, while the incidence of stage
II–IV disease increased less steeply. In women aged
under 50, though there was an increased incidence of
stage I cases, this was not accompanied by an increase in
the incidence of late-stage disease. For either sex, the
increase in incidence was steeper in the oldest patients
(≥70 years), and across age groups, increases in incidence
were steeper in men than women.
Strengths and limitations
The principal strengths of this analysis are the use of
population-based data covering an extensive period,
using high quality and highly complete information on
stage at diagnosis. To account for potential biases in
estimates arising from missing stage data, we used mul-
tiple imputation. Nonetheless, as shown in sensitivity
analyses, most estimates obtained from complete-case
analysis were similar to those obtained using multiple
imputed data.
The main limitation is that we cannot confidently infer
the causes of the observed stage-specific incidence
trends. Further analyses that consider changes in case-
mix over time of other disease factors, for example, in
tumour subsite (trunk, limbs, face, etc.) or diagnostic
route (e.g. identification through healthcare encounters
triggered by unrelated reasons), or in the rate of investi-
gations for suspected melanoma in the general popula-
tion, could help elucidate potential mechanisms. We
examined data from the former East Anglia cancer reg-
istry, a geographically-defined population of South
England whose residents are relatively older and more
affluent, and more likely to be of White ethnic origin,
compared with the rest of the English population [27].
These considerations might limit the generalizability of
the findings, though not their internal validity. Analyses
of England-wide data for the same 20-year era (to over-
come these generalizability limitations) are not possible
for our study period, because of the historically poor
nationwide completeness of stage information for
melanoma, until recent years. We examined the stratifi-
cation of stage-specific incidence by sex and age group,
but larger studies could additionally enable stratification
by socioeconomic status.
Comparisons with the literature
Our study indicates a continuation (to 2015) of previously
reported trends in our population (1991–2004) [13]. The
observed steeper increase in stage I incidence mirrors
upwards incidence rates of thin melanoma tumours
(< 1.5 mm), and incidence rates of melanoma in certain
subsites (e.g. trunk, head and neck) in studies covering
similar time periods in Denmark [28,29], Finland [30],
Scotland [31] and Northern England [32].
Implications for policy, practice and research
There are two main implications arising from the
findings. First, the observed trends are compatible with a
hypothesis of potential overdiagnosis of indolent cases,
across age groups but it would be wrong to assign all of
the increase in the incidence of melanoma to over-
diagnosis. Had this been the case, no increase in
advanced stage at diagnosis would have been observed in
men (all age groups) and women (age ≥50 years). Second,
the observed trends are also compatible with a hypothesis
of increasing rates of genuinely consequential illness for
older patients, particularly older men. Such a hypothesis
is supported by evidence from South-Eastern Europe,
where the increasing incidence of melanoma has been
accompanied by increasing mortality for men and women
aged 50 and older [33], and the USA, where increasing
incidence was not accompanied by any decrease in
tumour thickness for stage III and IV patients [34].
Quantifying the extent of overdiagnosis or increasing
rates of consequential disease in a population is chal-
lenging. Nevertheless, our data suggest that both appear
to be plausible, partial, explanations. These realizations
emphasize the importance of shared decision making
about investigating skin lesions and communication of
issues around overdiagnosis in conversations with
patients [35].
The 1–5% annual increase in advanced stage melanoma
(II–IV) in women aged 50 and older and men in all age
groups (Fig. 2 and Table 3), indicates a genuine increase
in late-stage melanoma, which accounts for a 50%
increase in incidence in older women and a 94% increase
in older men over the 20-year study period (Table 3).
This may reflect different risk behaviours with regard to
sun exposure or different biological behaviours of
melanoma in different age groups. The observation of
different patterns in the incidence of stage II–IV
melanoma women in the under 50s and those aged 50
and older warrants further investigation.
The increase in melanoma incidence puts pressure on
limited health service budgets, particularly with regard to
the use of novel, effective, but expensive biological
treatments for late-stage disease, which have become
available in recent years, offering life-extending man-
agement options. Our findings indicate an ongoing need
for public health education campaigns, to increase
6 Melanoma Research 2018, Vol 00 No 00
awareness of melanoma risk factors and symptoms and
achieve earlier diagnosis, particularly in the elderly, and
in men, who experienced the steepest increases in stage
II–IV disease.
Conclusion
The findings suggest that both a genuine increase in the
incidence of consequential illness and a degree of over-
diagnosis are likely to be responsible for the observed
increasing incidence trends in our population during the
study period. They also suggest that targeting of men and
older people in future public health awareness campaigns
may be justified.
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